Aratana Therapeutics (PETX) Shares are Up 0.86%

Aratana Therapeutics (PETX) : Traders are bullish on Aratana Therapeutics (PETX) as it has outperformed the S&P 500 by a wide margin of 6.82% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 0.7%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 0.86% in the last 1 week, and is up 6.24% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.

The stock has recorded a 20-day Moving Average of 2.31% and the 50-Day Moving Average is 7.67%.The 200 Day SMA reached 51.65%


Aratana Therapeutics (NASDAQ:PETX): After opening at $9, the stock dipped to an intraday low of $8.9 on Friday. However, the bulls stepped in to buy at lower levels and pushed the stock higher. The stock touched an intraday high of $9.39 and the buying power remained strong till the end. The stock closed at $9.36 for the day, a gain of 5.05% for the day session. The total traded volume was 842,982. The stocks close on the previous trading day was $9.36.

Aratana Therapeutics (PETX) has been rated by 6 research analysts. Fundamentally, the highest shorterm price forecast for the stock is expected to reach $18 and the lowest price target forecast is $9. The average forecast of all the analysts is $13 and the expected standard deviation is $3.16.

Aratana Therapeutics, Inc. is a pet therapeutics company focused on licensing, developing and commercializing of biopharmaceutical products for companion animals. The Company has licensed and is developing more than 18 therapeutic candidates in development consisting of small molecule pharmaceuticals and large molecule biologics that target serious medical conditions, such as pain and inflammation, stimulation of appetite, cancer and other serious diseases for dogs and cats. These product candidates are in various stages of development for the treatment of cats or dogs, or both. The Companys target indications include pain and inflammation associated with osteoarthritis, inappetence, post-operative pain, lymphoma, osteosarcoma, atopic dermatitis, ocular herpes and feline immunodeficiency virus. The Companys most advanced products from a development and commercialization perspective, AT-004 and AT-005, are monoclonal antibodies (MAbs) for treating lymphoma in dogs.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.